Mirum Pharmaceuticals
$43.33
19
+$2.96+7.33% Friday 20:00
Statistics
Day High
44.7
Day Low
39.7
52W High
44.7
52W Low
23.14
Volume
2,411,490
Avg. Volume
776,743
Mkt Cap
2.04B
P/E Ratio
-11.81
Dividend Yield
-
Dividend
-
Earnings
8MayConfirmed
Expected EPS
-0.48
Actual EPS
-0.54
People Also Follow
This list is based on the watchlists of people on Stock Events who follow MIRM. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap126.85B
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.08B
Gilead Sciences
GILD
Mkt Cap90.4B
Abbvie
ABBV
Mkt Cap304.29B
Pfizer
PFE
Mkt Cap169.83B
Novartis
NVS
Mkt Cap232.42B
Merck &
MRK
Mkt Cap318.55B
Astrazeneca
AZN
Mkt Cap244.04B
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
Analyst Ratings
53.56$Average Price Target
The highest estimate is $68.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
89%
Hold
11%
Sell
0%
About
Health Technology
Pharmaceuticals: Major
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Show more...
CEO
Employees
278
Country
US
ISIN
US6047491013
WKN
000A2PM29